Avita Medical (RCEL) vs Sight Sciences (SGHT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Sight Sciences (SGHT) has outperformed Avita Medical (RCEL) over the past year, gaining 144.1% versus a gain of 138.6%. Over five years, RCEL leads with a -24.9% price change compared with -60.6% for SGHT. Sight Sciences is the larger company by market cap ($466.6 million vs $412.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RCEL | SGHT |
|---|---|---|
| Share price | $13.33 | $8.47 |
| Market cap | $412.25M | $466.60M |
| 1-day change | +2.15% | 0.00% |
| YTD return | +278.26% | +6.81% |
| 1-year return | +138.57% | +144.09% |
| 5-year return | -24.87% | -60.60% |
| EPS (TTM) | $-1.43 | $-0.56 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $13.50 | $9.71 |
| 52-week low | $3.22 | $3.19 |
| Distance from 52-week high | -1.26% | -12.80% |
| Analyst consensus | none | buy |
| Avg. price target upside | -9.75% | +10.98% |
| Average volume | 441.70K | 254.06K |
| Shares outstanding | 30.93M | 55.09M |
| Employees | 226 | 186 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Avita Medical
RCEL stock →AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions.
Health Care · Medical/Dental Instruments · 226 employees
About Sight Sciences
SGHT stock →Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases in the United States. The company operates in two segments, Surgical Glaucoma and Dry Eye.
Health Care · Medical/Dental Instruments · 186 employees
RCEL vs SGHT FAQ
Which is bigger, Avita Medical or Sight Sciences?
Sight Sciences (SGHT) is larger, with a market capitalization of $466.60M compared with $412.25M for Avita Medical (RCEL).
Which stock has performed better over the past year, RCEL or SGHT?
SGHT returned +144.09% over the past 12 months, compared with +138.57% for RCEL (price return, excluding dividends). Past performance does not predict future results.
Are Avita Medical and Sight Sciences in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.